




Instance: composition-en-8efc3218e58b030bcc0685f059870454
InstanceOf: CompositionUvEpi
Title: "Composition for blitzima Package Leaflet"
Description:  "Composition for blitzima Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp7fc8cfe8242eb0119d3b2e1dc1d125b7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - blitzima"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Blitzima is and what it is used for </li>
<li>What you need to know before you use Blitzima </li>
<li>How to use Blitzima </li>
<li>Possible side effects </li>
<li>How to store Blitzima </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What blitzima is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What blitzima is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Blitzima is 
Blitzima contains the active substance  rituximab . This is a type of protein called a  monoclonal 
antibody . It sticks to the surface of a type of white blood cell called  B-Lymphocyte . When 
rituximab sticks to the surface of this cell, the cell dies. </p>
<p>What Blitzima is used for 
Blitzima may be used for the treatment of several different conditions in adults and children. Your 
doctor may prescribe Blitzima for the treatment of: </p>
<p>a) 
Non-Hodgkin s Lymphoma 
This is a disease of the lymph tissue (part of the immune system) that affects a type of white blood cell 
called B-Lymphocytes. 
In adults, Blitzima can be given alone or with other medicines called  chemotherapy . 
In adult patients where the treatment is working, Blitzima may be continued for 2 years after 
completing the initial treatment. 
In children and adolescents, Blitzima is given in combination with  chemotherapy . </p>
<p>b) 
Chronic lymphocytic leukaemia 
Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia. CLL affects a 
particular lymphocyte, the B cell, which originates from the bone marrow and develops in the lymph 
nodes. Patients with CLL have too many abnormal lymphocytes, which accumulate mainly in the bone 
marrow and blood. The proliferation of these abnormal B-lymphocytes is the cause of symptoms you 
may have. Blitzima in combination with chemotherapy destroys these cells which are gradually 
removed from the body by biological processes. </p>
<p>c) 
Granulomatosis with polyangiitis or microscopic polyangiitis 
Blitzima is used for the treatment of adults and children 2 years of age and older with granulomatosis 
with polyangiitis (formerly called Wegener s granulomatosis) or microscopic polyangiitis, taken in 
combination with corticosteroids. Granulomatosis with polyangiitis and microscopic polyangiitis are 
two forms of inflammation of the blood vessels which mainly affects the lungs and kidneys, but may 
affect other organs as well. B-lymphocytes are involved in the cause of these conditions. </p>
<p>d) 
Pemphigus vulgaris 
Blitzima is used for the treatment of patients with moderate to severe pemphigus vulgaris. Pemphigus 
vulgaris is an autoimmune condition that causes painful blisters on the skin and lining of the mouth, 
nose, throat and genitals. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take blitzima"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take blitzima"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Blitzima if 
* you are allergic to rituximab, other proteins which are like rituximab, or any of the other 
ingredients of this medicine (listed in section 6) 
* you have a severe active infection at the moment 
* you have a weak immune system 
* you have severe heart failure or severe uncontrolled heart disease and have granulomatosis with 
polyangiitis, microscopic polyangiitis or pemphigus vulgaris. </p>
<p>Do not have Blitzima if any of the above apply to you. If you are not sure, talk to your doctor, 
pharmacist or nurse before you are given Blitzima. </p>
<p>Warnings and precautions 
Talk to your doctor, pharmacist or nurse before you are given Blitzima if: </p>
<ul>
<li>you have ever had or might now have a hepatitis infection. This is because in a few cases, 
Blitzima could cause hepatitis B to become active again, which can be fatal in very rare cases. 
Patients who have ever had hepatitis B infection will be carefully checked by their doctor for 
signs of this infection. </li>
<li>you have ever had heart problems (such as angina, palpitations or heart failure) or breathing 
problems. </li>
</ul>
<p>If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before 
you are given Blitzima. Your doctor may need to take special care of you during your treatment with 
Blitzima. </p>
<p>If you have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris 
also tell your doctor 
* if you think you may have an infection, even a mild one like a cold. The cells that are affected 
by Blitzima help to fight infection and you should wait until the infection has passed before you 
are given Blitzima. Also please tell your doctor if you had a lot of infections in the past or suffer 
from severe infections. 
* if you think you may need any vaccinations in the near future, including vaccinations needed to 
travel to other countries. Some vaccines should not be given at the same time as Blitzima or in 
the months after you receive Blitzima. Your doctor will check if you should have any vaccines 
before you receive Blitzima. </p>
<p>Children and adolescents 
Non-Hodgkin s lymphoma 
Blitzima can be used for the treatment of children and adolescents, 6 months of age and older, with 
non-Hodgkin s lymphoma, specifically CD20 positive diffuse large B-cell lymphoma (DLBCL), 
Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like 
lymphoma (BLL). 
Talk to your doctor, pharmacist or nurse before you are given this medicine if you, or your child, are 
under 18 years of age. </p>
<p>Granulomatosis with polyangiitis or microscopic polyangiitis 
Blitzima can be used for treatment of children and adolescents, 2 years of age and older, with 
granulomatosis with polyangiitis (formerly called Wegener s granulomatosis) or microscopic 
polyangiitis. There is not much information about the use of Blitzima in children and adolescents with 
other diseases. 
Talk to your doctor, pharmacist or nurse before you are given this medicine if you, or your child, are 
under 18 years of age. </p>
<p>Other medicines and Blitzima 
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other 
medicines. This includes medicines obtained without a prescription and herbal medicines. This is 
because Blitzima can affect the way some other medicines work. Also some other medicines can affect 
the way Blitzima works. </p>
<p>In particular, tell your doctor: 
* if you are taking medicines for high blood pressure. You may be asked not to take these other 
medicines 12 hours before you are given Blitzima. This is because some people have a fall in 
their blood pressure while they are being given Blitzima. 
* if you have ever taken medicines which affect your immune system   such as chemotherapy or 
immune-suppressive medicines. </p>
<p>If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before 
you are given Blitzima. </p>
<p>Pregnancy and breast-feeding 
You must tell your doctor or nurse if you are pregnant, think that you might be pregnant or are 
planning to become pregnant. This is because Blitzima can across the placenta and may affect 
your baby. </p>
<p>If you can get pregnant, you and your partner must use an effective method of contraception 
while using Blitzima. You must also do this for 12 months after your last treatment with 
Blitzima. </p>
<p>Blitzima passes into breast milk in very small amounts. As the long-term effects on breastfed infants 
are not known, for precautionary reasons, breast-feeding is not recommended during treatment with 
Blitzima and for 6 months after the treatment. </p>
<p>Driving and using machines 
Rituximab has no or negligible influence on the ability to drive and use machines.  </p>
<p>Blitzima contains sodium 
This medicine contains 52.6 mg sodium (main component of cooking/table salt) in each 10 mL vial 
and 263.2 mg sodium (main component of cooking/table salt) in each 50 mL vial.<br />
This is equivalent to 2.6% (for 10 mL vial) and 13.2% (for 50 mL vial) of the recommended maximum 
daily dietary intake of sodium for an adult. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take blitzima"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take blitzima"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>How Blitzima is given 
Blitzima will be given to you by a doctor or nurse who is experienced in the use of this treatment. 
They will watch you closely while you are being given this medicine. This is in case you get any 
side effects. 
You will always be given Blitzima as a drip (intravenous infusion). </p>
<p>Medicines given before each Blitzima administration 
Before you are given Blitzima, you will be given other medicines (pre-medication) to prevent or 
reduce possible side effects. </p>
<p>How much and how often you will receive your treatment 
a) 
If you are being treated for non-Hodgkin s Lymphoma 
* If you are having Blitzima alone 
Blitzima will be given to you once a week for 4 weeks. Repeated treatment courses with 
Blitzima are possible. 
* If you are having Blitzima with chemotherapy 
Blitzima will be given to you on the same day as your chemotherapy. This is usually given 
every 3 weeks up to 8 times. 
* If you respond well to treatment, you may be given Blitzima every 2 or 3 months for two 
years. Your doctor may change this, depending on how you respond to the medicine. 
* If you are less than 18 years of age, you will be given Blitzima with chemotherapy. You will 
receive Blitzima up to 6 times over a 3.5   5.5 month period. </p>
<p>b) 
If you are being treated for chronic lymphocytic leukaemia 
When you are treated with Blitzima in combination with chemotherapy, you will receive Blitzima 
infusions on day 0 cycle 1 then day 1 of each cycle for 6 cycles in total. Each cycle has a duration of 
28 days. The chemotherapy should be given after the Blitzima infusion. Your doctor will decide if 
you should receive concomitant supportive therapy. </p>
<p>c) 
If you are being treated for granulomatosis with polyangiitis or microscopic polyangiitis<br />
Treatment with Blitzima uses four separate infusions given at weekly intervals. Corticosteroids will 
usually be given by injection before the start of Blitzima treatment. Corticosteroids given by mouth 
may be started at any time by your doctor to treat your condition. If you are 18 years of age and 
older and respond well to treatment, you may be given Blitzima as a maintenance treatment. This 
will be administered as 2 separate infusions which are given 2 weeks apart, followed by 1 infusion 
every 6 months for at least 2 years. Your doctor may decide to treat you longer with Blitzima (up to 
5 years), depending on how you respond to the medicine. </p>
<p>d) 
If you are being treated for pemphigus vulgaris 
Each course of treatment is made up of two separate infusions which are given 2 weeks apart. If you 
respond well to treatment, you may be given Blitzima as a maintenance treatment. This will be 
administered 1 year and 18 months after the initial treatment and then every 6 months as needed or 
your doctor may change this, depending on how you respond to the medicine. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Most side effects are mild to moderate but some may be serious and require treatment. Rarely, some of 
these reactions have been fatal. </p>
<p>Infusion reactions 
During or within the first 24 hours of the infusion you may develop fever, chills and shivering. Less 
frequently, some patients may experience pain at the infusion site, blisters, itching, sickness 
(nausea), tiredness, headache, breathing difficulties, blood pressure raised, wheezing, throat 
discomfort, tongue or throat swelling, itchy or runny nose, vomiting, flushing or palpitations, heart 
attack or low number of platelets. If you have heart disease or angina, these reactions might get 
worse. Tell the person giving you the infusion immediately if you or your child develops any of 
these symptoms, as the infusion may need to be slowed down or stopped. You may require 
additional treatment such as an antihistamine or paracetamol. When these symptoms go away, or 
improve, the infusion can be continued. These reactions are less likely to happen after the second 
infusion. Your doctor may decide to stop your Blitzima treatment if these reactions are serious. </p>
<p>Infections 
Tell your doctor immediately if you or your child gets signs of an infection including: </p>
<ul>
<li>fever, cough, sore throat, burning pain when passing urine or feeling weak or generally unwell </li>
<li>memory loss, trouble thinking, difficulty walking or sight loss   these may be due to a very rare, 
serious brain infection, which has been fatal (progressive multifocal leukoencephalopathy or 
PML). </li>
<li>fever, headache and stiff neck, incoordination (ataxia), personality change, hallucinations, 
altered consciousness, seizures or coma   these may be due to a serious brain infection 
(enteroviral meningoencephalitis), which can be fatal. </li>
</ul>
<p>You might get infections more easily during your treatment with Blitzima. 
These are often colds, but there have been cases of pneumonia,  urinary infections and serious viral 
infections. These are listed below under  Other side effects . </p>
<p>If you are being treated for granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus 
vulgaris, you will also find this information in the Patient Alert Card you have been given by your 
doctor. It is important that you keep this Alert Card and show it to your partner or caregiver. </p>
<p>Skin reactions 
Very rarely, severe blistering skin conditions that can be life-threatening may occur. Redness, often 
associated with blisters, may appear on the skin or on mucous membranes, such as inside the mouth, 
the genital areas or the eyelids, and fever may be present. Tell your doctor immediately if you have 
any of these symptoms. </p>
<p>Other side effects include: </p>
<p>a) 
If you or your child are being treated for non-Hodgkin s Lymphoma or chronic 
lymphocytic leukaemia </p>
<p>Very common side effects (may affect more than 1 in 10 people): 
* bacterial or viral infections, bronchitis 
* low number of white blood cells, with or without fever or blood cells called  platelets<br />
* feeling sick (nausea) 
* bald spots on the scalp, chills, headache 
* lower immunity   because of lower levels of anti-bodies called  immunoglobulins  (IgG) 
in the blood which help protect against infection </p>
<p>Common side effects (may affect up to 1 in 10 people): 
* infections of the blood (sepsis), pneumonia, shingles, cold, bronchial tube infections, 
fungal infections, infections of unknown origin, sinus inflammation, hepatitis B 
* low number of red blood cells (anaemia), low number of all blood cells 
* allergic reactions (hypersensitivity) 
* high blood sugar level, weight loss, swelling in the face and body, high levels of the 
enzyme  lactate dehydrogenase (LDH)  in the blood, low calcium levels in the blood 
* unusual feelings of the skin   such as numbness, tingling, pricking, burning, a creeping 
skin feeling, reduced sense of touch 
* feeling restless, problems falling asleep, 
* becoming very red in the face and other areas of the skin as a consequence of dilation of 
the blood vessels 
* feeling dizzy or anxious 
* producing more tears, tear duct problems, inflamed eye (conjunctivitis) 
* ringing sound in the ears, ear pain 
* heart problems   such as heart attack, uneven or fast heart rate 
* high or low blood pressure (low blood pressure especially when standing upright) 
* tightening of the muscles in the airways which causes wheezing (bronchospasm), 
inflammation, irritation in the lungs, throat or sinuses, being short of breath, runny 
nose 
* being sick (vomiting), diarrhoea, pain in the stomach, irritation or ulcers in the throat 
and mouth, problems swallowing, constipation, indigestion 
* eating disorders, not eating enough, leading to weight loss 
* hives, increased sweating, night sweats 
* muscle problems   such as tight muscles, joint or muscle pain, back and neck pain 
* general discomfort or feeling uneasy or tired, shaking, signs of flu 
* multiple-organ failure. </p>
<p>Uncommon side effects (may affect up to 1 in 100 people): 
* blood clotting problems, decrease of red blood cell production and increase of red blood 
cell destruction (aplastic haemolytic anaemia), swollen or enlarged lymph nodes 
* low mood and loss of interest or enjoyment in doing things, feeling nervous 
* taste problems   such as changes in the way things taste 
* heart problems   such as reduced heart rate or chest pain (angina) 
* asthma, too little oxygen reaching the body organs 
* swelling of the stomach. </p>
<p>Very rare side effects (may affect up to 1 in 10,000 people): 
* short term increase in the amount of some types of anti-bodies in the blood (called 
immunoglobulins   IgM), chemical disturbances in the blood caused by break-down of 
dying cancer cells 
* nerve damage in arms and legs, paralysed face 
* heart failure 
* inflammation of blood vessels including those leading to skin symptoms 
* respiratory failure 
* damage to the intestinal wall (perforation) 
* severe skin problems causing blisters that can be life-threatening. Redness, often 
associated with blisters, may appear on the skin or on mucous membranes, such as inside 
the mouth, the genital areas or the eyelids, and fever may be present. 
* kidney failure 
* severe vision loss </p>
<p>Not known (it is not known how often these side effects happen): 
* a reduction in white blood cells which does not happen straight away 
* reduced platelets number just after the infusion   this can be reversed, but can be fatal in 
rare cases 
* hearing loss, loss of other senses 
*  brain and meningeal infection/inflammation (enteroviral meningoencephalitis) </p>
<p>Children and adolescents with non-Hodgkin s lymphoma 
In general, side effects in children and adolescents with non-Hodgkin s lymphoma were similar to 
those in adults with non-Hodgkin s lymphoma or chronic lymphocytic leukaemia. The most common 
side effects seen were fever associated with low levels of a type of white blood cell (neutrophil), 
inflammation or sores in the lining of the mouth, and allergic reactions (hypersensitivity). </p>
<p>b) 
If you or your child are being treated for granulomatosis with polyangiitis or microscopic 
polyangiitis </p>
<p>Very common side effects (may affect more than 1 in 10 people): 
* infections, such as chest infections, urinary tract infections (pain on passing water), colds 
and herpes infections 
* allergic reactions that are most likely to occur during an infusion, but can occur up to 24-
hours after infusion 
* diarrhoea 
* coughing or shortness of breath 
* nose bleeds 
* raised blood pressure 
* painful joints or back 
* muscle twitches or shakiness 
* feeling dizzy 
* tremors (shakiness, often in the hands) 
* difficulty sleeping (insomnia) 
* swelling of the hands or ankles </p>
<p>Common side effects (may affect up to 1 in 10 people): 
* indigestion 
* constipation 
* skin rashes, including acne or spots 
* flushing or redness of the skin 
* fever 
* blocked or runny nose 
* tight or painful muscles 
* pain in the muscles or in the hands or feet 
* low number of red blood cells (anaemia) 
* low numbers of platelets in the blood 
* an increase in the amount of potassium in the blood 
* changes in the rhythm of the heart, or the heart beating faster than normal </p>
<p>Very rare side effects (may affect up to 1 in 10,000 people): 
* severe blistering skin conditions that can be life-threatening. Redness, often associated 
with blisters, may appear on the skin or on mucous membranes, such as inside the 
mouth, the genital areas or the eyelids, and fever may be present. 
* recurrence of a previous Hepatitis B infection </p>
<p>Not known (frequency cannot be estimated from the available data): 
* serious viral infection 
* brain and meningeal infection/inflammation (enteroviral meningoencephalitis) </p>
<p>Children and adolescents with granulomatosis with polyangiitis or microscopic polyangiitis 
In general, side effects in children and adolescents with granulomatosis with polyangiitis or 
microscopic polyangiitis were of a similar type to those in adults with granulomatosis with 
polyangiitis or microscopic polyangiitis. Most common side effects seen were infections, allergic 
reactions and feeling sick (nausea). </p>
<p>c) 
If you are being treated for pemphigus vulgaris </p>
<p>Very common side effects (may affect more than 1 in 10 people): 
* allergic reactions that are most likely to occur during an infusion, but can occur up to 24 hours 
after infusion 
* headache 
* infections such as chest infections 
* long lasting depression 
* loss of hair </p>
<p>Common side effects (may affect up to 1 in 10 people): 
* infections such as common cold, herpes infections, eye infection, oral thrush and urinary tract 
infections (pain on passing urine) 
* mood disorders such as irritability and depression 
* skin disorders such as itching, hives, and benign lumps 
* feeling tired or dizzy 
* fever 
* painful joints or back 
* pain in the tummy 
* pain in the muscles 
* heart beating faster than normal 
Not known (frequency cannot be estimated from the available data): 
* serious viral infection 
* brain and meningeal infection/inflammation (enteroviral meningoencephalitis) </p>
<p>Blitzima may also cause changes in laboratory tests carried out by your doctor. 
If you are having Blitzima with other medicines, some of the side effects you may get may be due to 
the other medicines. </p>
<p>Reporting of side effects </p>
<p>If you get any side effects talk to your doctor, pharmacist or nurse. This includes any side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store blitzima"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store blitzima"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP. 
The expiry date refers to the last day of that month. </p>
<p>Store in a refrigerator (2  C   8  C). Keep the vial in the outer carton in order to protect from light. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how 
to throw away medicines that you no longer use. These measures will help protect the 
environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Blitzima contains 
* The active ingredient in Blitzima is called rituximab.<br />
The 10 mL vial contains 100 mg of rituximab (10 mg/mL).<br />
The 50 mL vial contains 500 mg of rituximab (10 mg/mL). </p>
<ul>
<li>The other ingredients are sodium chloride, tri-sodium citrate dihydrate, polysorbate 80 and 
water for injections (see section 2  Blitzima contains sodium ). </li>
</ul>
<p>What Blitzima looks like and contents of the pack </p>
<p>Blitzima is a clear, colourless solution, supplied as a concentrate for solution for infusion.<br />
10 mL vial   Pack of 2 vials 
50 mL vial   Pack of 1 vial </p>
<p>Marketing Authorisation Holder </p>
<p>Celltrion Healthcare Hungary Kft.<br />
1062 Budapest 
V ci  t 1-3. WestEnd Office Building B torony 
Hungary </p>
<p>Manufacturer </p>
<p>Millmount Healthcare Ltd. 
Block 7, City North Business Campus,<br />
Stamullen, Co. Meath K32 YD60,<br />
Ireland </p>
<p>Nuvisan GmbH 
Wegenerstrasse 13, Ludwigsfeld 
89231 Neu-Ulm, Bavaria 
Germany </p>
<p>Nuvisan France SARL<br />
2400, Route des Colles, 06410, Biot,<br />
France </p>
<p>KYMOS S.L. 
Ronda de Can Fatj , 7B Parc Tecnol gic del Vall s 
08290   Cerdanyola del Vall s, Barcelona,<br />
Spain </p>
<p>Midas Pharma GmbH<br />
Rheinstrasse 49, West Ingelheim Am Rhein,<br />
Rhineland-Palatinate 55218 Ingelheim,<br />
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Celltrion Healthcare Belgium BVBA 
BEinfo@celltrionhc.com 
Lietuva 
Celltrion Healthcare Hungary Kft. 
Tel: +36 1 231 0<br />
Celltrion Healthcare Hungary Kft. 
Tel: +36 1 231 0Luxembourg/Luxemburg 
Celltrion Healthcare Belgium BVBA 
BEinfo@celltrionhc.com 
 esk  republika 
Celltrion Healthcare Hungary Kft. 
Tel: +36 1 231 0Magyarorsz g 
Celltrion Healthcare Hungary Kft. 
Tel: +36 1 231 0Danmark 
Orion Pharma A/S<br />
Tlf: + 45 86 14 00 Malta 
Mint Health Ltd. 
Tel: +356 2093 9Deutschland 
Celltrion Healthcare Deutschland GmbH 
Tel. +49 (0)30 346494infoDE@celltrionhc.com 
Nederland 
Celltrion Healthcare Netherlands B.V. 
NLinfo@celltrionhc.com </p>
<p>Eesti 
Orion Pharma Eesti O  </p>
<p>Norge 
Orion Pharma AS 
Tel: + 372 6 644 Tlf: + 47 40 00 42 <br />
   . . 
 : +30 210 8009111   Espa a 
Kern Pharma, S.L. 
Tel: +34 93 700 2 sterreich 
Astro-Pharma GmbH 
Tel: +43 1 97 99 Polska 
EGIS Polska Sp. z o.o. 
Tel.: + 48 22 417 9France 
CELLTRION HEALTHCARE FRANCE SAS 
T l: +33 (0)1 71 25 27 Portugal 
PharmaKERN Portugal   Produtos Farmac uticos, 
Sociedade Unipessoal, Lda. 
Tel: +351 214 200 Hrvatska 
Oktal Pharma d.o.o. 
Tel: +385 1 6595 Rom nia 
Celltrion Healthcare Hungary Kft. 
Tel: +36 1 231 0Ireland 
Celltrion Healthcare Ireland Limited 
enquiry_ie@celltrionhc.com </p>
<p>Slovenija 
OPH Oktal Pharma d.o.o.<br />
Tel: +386 1 519 29  sland 
Vistor hf.<br />
S mi: +354 535 7Slovensk  republika 
Celltrion Healthcare Hungary Kft. 
Tel: +36 1 231 0Italia 
Celltrion Healthcare Italy S.R.L 
Tel: +39 0427 927Celltrionhealthcare_italy@legalmail.it 
Suomi/Finland 
Orion Pharma 
Puh/Tel: + 358 10 4<br />
C.A. Papaellinas Ltd 
 : +357 22741Sverige 
Orion Pharma AB 
Tel: + 46 8 623 64 Latvija 
Celltrion Healthcare Hungary Kft. 
Tel: +36 1 231 0United Kingdom (Northern Ireland) 
Celltrion Healthcare Ireland Limited 
Tel: +353 1 223 4enquiry_ie@celltrionhc.com </p>
<p>This leaflet was last revised in </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-8efc3218e58b030bcc0685f059870454
InstanceOf: CompositionUvEpi
Title: "Composition for blitzima Package Leaflet"
Description:  "Composition for blitzima Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp7fc8cfe8242eb0119d3b2e1dc1d125b7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - blitzima"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at få Blitzima 
3. Sådan får du Blitzima 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelse og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What blitzima is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What blitzima is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Virkning 
Blitzima indeholder det aktive indholdsstof rituximab. Det er en type protein, der kaldes et 
monoklonalt antistof. Det binder sig til overfladen på de hvide blodlegemer, der kaldes B-lymfocytter. 
Når rituximab bindes til overfladen af denne celle, dør cellen til at dø. </p>
<p>Anvendelse 
Blitzima kan anvendes til behandling af flere forskellige tilstande hos voksne og børn. Din læge kan 
ordinere Blitzima til behandling for: </p>
<p>a) 
Non-Hodgkin-lymfom 
Non-Hodgkin-lymfom er en sygdom i lymfesystemet (en del af immunsystemet), der påvirker de 
hvide blodlegemer, der kaldes B-lymfocytter. 
Hos voksne kan Blitzima anvendes alene eller sammen med kemoterapi. 
Hvis behandlingen virker, kan Blitzima fortsættes i 2 år efter, den første behandling er givet. 
Hos børn og unge anvendes Blitzima sammen med kemoterapi. </p>
<p>b) 
Kronisk lymfatisk leukæmi 
Kronisk lymfatisk leukæmi (CLL) er den almindeligste form for leukæmi hos voksne. CLL påvirker 
en bestemt lymfocyt, nemlig B-cellen, som findes i knoglemarven og dannes i lymfeknuderne. 
Patienter med CLL har for mange unormale lymfocytter, som hovedsageligt ophobes i knoglemarven 
og blodet. Det er formeringen af disse unormale B-lymfocytter, der er årsagen til de symptomer, du 
kan have. Blitzima anvendt sammen med kemoterapi ødelægger disse celler, som gradvis fjernes fra 
kroppen ved biologiske processer. </p>
<p>c) 
Granulomatose med polyangiitis eller mikroskopisk polyangiitis 
Blitzima gives i kombination med binyrebarkhormon, for at behandle sygdommen granulomatose med 
polyangiitis (blev tidligere kaldt Wegeners granulomatose) og mikroskopisk polyangiitis. 
Granulomatose med polyangiitis og mikroskopisk polyangiitis er to former for inflammation 
(betændelse) i blodkarrene. Det er som regel lunger og nyrer, der bliver påvirket, men sygdommene 
kan også påvirke andre organer. B-lymfocytter er involveret i årsagen til disse tilstande hos voksne og 
børn på 2 år og opefter. </p>
<p>d)      Pemfigus vulgaris 
Blitzima anvendes til behandling af patienter med moderat til svær pemfigus vulgaris. Pemfigus 
vulgaris er en autoimmun sygdom, der forårsager smertefulde blærer på huden og mundens, næsens, 
halsens og kønsorganernes slimhinder. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take blitzima"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take blitzima"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få Blitzima, hvis: </p>
<ul>
<li>
<p>du er allergisk over for rituximab, andre proteiner, der ligner rituximab eller et af de øvrige 
indholdsstoffer i Blitzima (angivet i punkt 6). </p>
</li>
<li>
<p>du i øjeblikket har en aktiv svær infektion </p>
</li>
<li>
<p>du har et svagt immunforsvar. </p>
</li>
<li>
<p>du har svært nedsat hjertefunktion eller svær, ukontrolleret hjertesygdom og har granulomatose 
med polyangiitis, mikroskopisk polyangiitis eller pemfigus vulgaris. </p>
</li>
</ul>
<p>Du må ikke få Blitzima, hvis ét eller flere af ovenstående punkter gælder for dig. Hvis du er i tvivl, 
skal du kontakte lægen, apotekspersonalet eller sundhedspersonalet, inden du får Blitzima. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sundhedspersonalet, inden du får Blitzima, hvis: </p>
<ul>
<li>
<p>du nogensinde har haft leverbetændelse eller måske har leverbetændelse nu. Det er vigtigt, fordi 
Blitzima i enkelte tilfælde har forårsaget, at en tidligere leverbetændelse (hepatitis B) er blevet 
aktiv igen. Dette kan i sjældne tilfælde være dødeligt. Patienter, som en gang har haft 
leverbetændelse, vil blive omhyggeligt undersøgt af lægen for tegn på denne infektion </p>
</li>
<li>
<p>du nogensinde har haft hjerteproblemer (f.eks. angina, hjertebanken eller hjertesvigt) eller 
vejrtrækningsbesvær. </p>
</li>
</ul>
<p>Hvis ét eller flere af ovenstående punkter gælder for dig (eller du er i tvivl), skal du kontakte lægen, 
apotekspersonalet eller sundhedspersonalet, inden du får Blitzima. Du kan have behov for ekstra 
overvågning under din behandling med Blitzima. </p>
<p>Hvis du har granulomatose med polyangiitis, mikroskopisk polyangiitis fortæl da også din læge 
eller pemfigus vulgaris </p>
<ul>
<li>
<p>hvis du tror, du måske har en infektion, selv en mild form som for eksempel en forkølelse. 
Cellerne, der påvirkes af Blitzima hjælper med at bekæmpe infektioner, og du bør vente med 
behandling med Blitzima, indtil infektionen er forsvundet. Fortæl også lægen, hvis du tidligere 
har haft mange infektioner eller lider af alvorlige infektioner </p>
</li>
<li></li>
</ul>
<p>Børn og unge 
Non-Hodgkin-lymfom 
Blitzima kan bruges til behandling af børn og unge i alderen 6 måneder og derover, som har non-
Hodgkin-lymfom, særligt CD20 positivt diffust storcellet B-celle lymfom (DLBCL), Burkitt lymfom 
(BL)/Burkitt leukæmi (akut leukæmi i modne B-celler) (B-ALL) eller Burkitt-lignende lymfom (BLL). 
Kontakt lægen, apotekspersonalet eller sundhedspersonalet, inden medicinen gives, hvis du eller dit 
barn er under 18 år. </p>
<p>Granulomatose med polyangiitis eller mikroskopisk polyangiitis 
Blitzima kan anvendes til behandling af børn og unge på 2 år og opefter, med granulomatose med 
polyangiitis (tidligere kaldet Wegeners granulomatose) eller mikroskopisk polyangiitis. Der er ikke 
meget information om brugen af Blitzima hos børn og unge med andre sygdomme. </p>
<p>Du skal kontakte lægen, apotekspersonalet eller sundhedspersonalet, inden medicinen gives, hvis du 
eller dit barn er under 18 år. </p>
<p>Brug af anden medicin sammen med Blitzima 
Fortæl lægen, apotekspersonalet eller sundhedspersonalet om al medicin du tager i øjeblikket, har taget 
for nyligt eller planlægger at tage. Det gælder også medicin, der ikke er på recept, og naturlægemidler. 
Det er vigtigt, da Blitzima kan påvirke virkningen af anden medicin, og anden medicin kan påvirke 
virkningen af Blitzima. </p>
<p>Det er særligt vigtigt at fortælle lægen: </p>
<ul>
<li>
<p>om du tager medicin mod forhøjet blodtryk. Du kan blive bedt om ikke at tage denne medicin i 
12 timer inden, du får Blitzima. Nogle har oplevet, at blodtrykket faldt, mens de fik Blitzima </p>
</li>
<li>
<p>om du nogensinde har fået medicin, der påvirker immunforsvaret, f.eks. kemoterapi eller 
medicin, der nedsætter immunforsvaret. </p>
</li>
</ul>
<p>Hvis ét eller flere af ovenstående punkter gælder for dig (eller du er i tvivl), skal du kontakte lægen, 
apotekspersonalet eller sundhedspersonalet, inden du får Blitzima. </p>
<p>Graviditet og amning 
Du skal kontakte lægen eller sundhedspersonalet, hvis du er gravid, tror, du måske kan være gravid 
eller planlægger at blive gravid. Blitzima kan overføres til moderkagen og påvirke barnet. 
Hvis du er i den fødedygtige alder, skal du og din partner bruge sikker prævention, mens du er i 
behandling med Blitzima. I skal fortsætte med sikker prævention i 12 måneder efter din sidste 
behandling med Blitzima. 
Blitzima udskilles i modermælk i meget små mængder. Idet langtidseffekten på ammende spædbørn er 
ukendt, anbefales amning, af forsigtighedsmæssige årsager, i ikke under behandling med Blitzima og i 
op til 6 måneder derefter. </p>
<p>Trafik og arbejdssikkerhed 
Rituximab har ingen eller ubetydelig indflydelse på evnen til at føre motorkøretøj og betjene maskiner  </p>
<p>Blitzima indeholder natrium 
Denne medicin indeholder 52,6 mg natrium (hovedbestanddelen i køkkensalt/bordsal) i hvert 10 mL 
hætteglas og 263,2 mg natrium (hovedbestanddelen i køkkensalt/bordsal) i hvert 50 mL hætteglas. 
Dette svarer til 2,6 % (for 10 mL hætteglas) og 13,2 % (for 50 mL hætteglas) af det anbefalede 
maksimale daglige indtag af natrium for en voksen. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take blitzima"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take blitzima"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sådan gives Blitzima </p>
<p>Du får Blitzima af en læge eller sygeplejerske med erfaring i denne behandling. De vil overvåge dig, 
mens du får medicinen. Dette er i tilfælde af, at du skulle få bivirkninger. 
Blitzima gives altid i et drop (intravenøs infusion). </p>
<p>Medicin, der gives inden hver behandling med Blitzima 
Inden du får Blitzima, vil du få anden medicin (præmedicin), der forebygger eller mindsker mulige 
bivirkninger. </p>
<p>Hvor meget medicin skal du have og hvor ofte? </p>
<p>a) 
Hvis du behandles for non-Hodgkin-lymfom </p>
<ul>
<li>
<p>Hvis du får Blitzima alene 
Blitzima gives en gang ugentligt i 4 uger. Gentagne behandlingsforløb med Blitzima er mulige. </p>
</li>
<li>
<p>Hvis du får Blitzima sammen med kemoterapi 
Blitzima gives samme dag som kemoterapien. Det vil sædvanligvis sige hver 3. uge, op til 
8 gange. </p>
</li>
<li>
<p>Hvis medicinen virker godt hos dig, kan du få Blitzima hver 2. eller 3. måned i op til 2 år. 
Lægen kan ændre dette afhængigt af, hvorledes medicinen virker på dig. </p>
</li>
<li>
<p>Hvis du er under 18 år, vil du få Blitzima sammen med kemoterapi. Du vil få Blitzima op til 6 
gange i en periode på 3,5 – 5,5 måneder. </p>
</li>
</ul>
<p>b) 
Hvis du behandles for kronisk lymfatisk leukæmi 
Hvis du behandles med Blitzima i kombination med kemoterapi, vil du få en infusion med Blitzima på 
dag 0 i serie 1 og derefter på dag 1 i hver af i alt 6 serier. Hver serie varer 28 dage. Kemoterapien skal 
gives efter infusionen med Blitzima. Din læge vil tage stilling til, om du samtidig skal have 
understøttende behandling. </p>
<p>c) 
Hvis du behandles for granulomatose med polyangiitis eller mikroskopisk polyangiitis 
Hvert behandlingsforløb består af fire separate infusioner, der gives med én uges mellemrum. Du vil 
som regel få en indsprøjtning med binyrebarkhormon, inden behandlingen med Blitzima påbegyndes. 
Lægen kan give dig binyrebarkhormon-tabletter på et hvilket som helst tidspunkt for at behandle din 
tilstand. Hvis du er 18 år eller derover og reagerer godt på behandlingen kan du få Blitzima som 
vedligeholdesesbehandling. Dette vil blive givet som to separate infusioner med to ugers mellemrum, 
efterfulgt af én infusion hver 6. måned i mindst 2 år. Din læge kan beslutte at behandle dig i længere 
tid med Blitzima (op til 5 år), alt efter hvor godt du reagerer på medicinen. </p>
<p>d)        Hvis du behandles for pemfigus vulgaris 
Hvert behandlingsforløb består af to separate infusioner, der gives med 2 ugers mellemrum. Hvis du 
reagerer godt på behandlingen, kan du få Blitzima som vedligeholdelsesbehandling. 
Vedligeholdelsesbehandling vil gives 1 år og 18 måneder efter behandlingens start og herefter hver 6. måned efter behov. Din læge kan ændre dette, afhængigt af hvordan du reagerer på behandlingen. </p>
<p>Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis det er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. De 
fleste bivirkninger er lette til moderate men nogle kan være alvorlige og kræve behandling. Sjældent 
har nogle af disse bivirkninger været dødelige. </p>
<p>Infusionsreaktioner 
Under eller inden for de første 24 timer af infusionen kan du få feber, kuldegysninger og rysten. 
Mindre hyppigt kan nogle patienter opleve smerte ved infusionsstedet, blærer, hudkløe, kvalme, 
træthed, hovedpine, vejrtrækningsbesvær, øget blodtryk, hvæsen, ubehag i halsen, hævelse af tunge 
eller hals, kløende eller løbende næse, opkastning, rødme eller hjertebanken, hjerteanfald eller lavt 
antal blodplader. Hvis du har hjerteproblemer eller angina pectoris kan symptomerne forværres. 
Fortæl det straks til den person, der giver dig infusionen, hvis du eller dit barn oplever nogle af 
disse symptomer, da infusionshastigheden måske skal nedsættes eller stoppes. Du kan behøve 
yderligere behandling som antihistamin eller paracetamol. Når disse symptomer forsvinder eller 
forbedres, kan infusionen fortsættes. Ved de efterfølgende infusioner vil hyppigheden af disse 
reaktioner være mindre. Hvis disse reaktioner er alvorlige, kan lægen vælge at stoppe behandlingen 
med Blitzima. </p>
<p>Infektioner 
Kontakt straks lægen, hvis du eller dit barn får tegn på infektion, f.eks.: </p>
<ul>
<li>
<p>feber, hoste, ondt i halsen, brændende smerte ved vandladning eller følelse af svaghed eller 
almen utilpashed </p>
</li>
<li>
<p>hukommelsestab, koncentrationsbesvær, besvær med at gå eller synstab – dette kan skyldes en 
meget sjælden, alvorlig hjerneinfektion, der i nogle tilfælde har været dødelig (progressiv 
multifokal leukoencefalopati eller PML). </p>
</li>
<li>
<p>feber, hovedpine, stiv nakke, usikre bevægelser (ataksi), personlighedsforandringer, 
hallucinationer, påvirket bevidsthed, kramper eller koma - dette kan skyldes en alvorlig 
hjerneinfektion (enteroviral meningoencefalitis), der kan være dødelig. </p>
</li>
</ul>
<p>Risikoen for infektioner kan øges under behandling med Blitzima. Det vil ofte dreje sig om forkølelser, 
men der har været tilfælde af lungebetændelse, urinvejsinfektioner og alvorlige virusinfektioner. <br />
Disse er angivet under ”Andre bivirkninger”. </p>
<p>Hvis du behandles for granulomatose med polyangiitis, mikroskopisk polyangiitis eller pemfigus 
vulgaris vil du også finde denne information i patientkortet, som du har fået af lægen. Det er vigtigt, at 
du gemmer dette kort og viser det til din partner eller hjælper. </p>
<p>Hudsygdomme 
Meget sjældent kan der forekomme alvorlige, eventuelt livstruende hudsygdomme med blærer. Rødme, 
ofte forbundet med blærer, kan forekomme på hud og slimhinder såsom på indersiden af munden, 
kønsdele eller øjenlåg og kan være ledsaget af feber. Fortæl det øjeblikkeligt til lægen, hvis du 
oplever nogen af disse symptomer. </p>
<p>Andre bivirkninger omfatter: 
a) 
Hvis du eller dit barn behandles for non-Hodgkin-lymfom eller kronisk lymfatisk 
leukæmi 
Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 patienter): </p>
<ul>
<li>
<p>bakterie-eller virusinfektioner, bronkitis </p>
</li>
<li>
<p>lavt antal hvide blodlegemer med eller uden feber eller lavt antal blodplader </p>
</li>
<li>
<p>kvalme </p>
</li>
<li>
<p>skaldede pletter i hårbunden, kulderystelser, hovedpine </p>
</li>
<li>
<p>lavt immunforsvar, fordi indholdet af antistoffer i blodet, som beskytter mod infektion, 
kaldet immunglobuliner (IgG), falder. </p>
</li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter): </p>
<ul>
<li>
<p>infektioner i blodet (sepsis), lungebetændelse, helvedesild, forkølelse, infektion i bronkierne, 
svampeinfektioner, infektioner af ukendt oprindelse, bihulebetændelse, leverbetændelse 
(hepatitis B) </p>
</li>
<li>
<p>lavt antal røde blodlegemer (anæmi), lavt antal af alle blodlegemer </p>
</li>
<li>
<p>allergiske reaktioner (overfølsomhed) </p>
</li>
<li>
<p>højt blodsukker, vægttab, hævelse i ansigt og krop, høje niveauer af enzymet 
laktatdehydrogenase (LDH) i blodet, lavt indhold af kalk i blodet </p>
</li>
<li>
<p>usædvanlig følelse i huden, f.eks. følelsesløshed, prikken, stikken, brænden, myrekryb, 
nedsat følesans </p>
</li>
<li>
<p>rastløshed, søvnproblemer </p>
</li>
<li>
<p>udtalt rødme i ansigtet og andre områder af huden på grund af udvidede blodkar </p>
</li>
<li>
<p>svimmelhed, nervøsitet </p>
</li>
<li>
<p>tåreflåd, problemer med tårekanaler, irriterede øjne (konjunktivitis) </p>
</li>
<li>
<p>ringen for ørerne, øresmerter </p>
</li>
<li>
<p>hjerteproblemer, f.eks. hjerteanfald, uregelmæssig eller hurtig hjerteaktion (puls) </p>
</li>
<li>
<p>højt eller lavt blodtryk (lavt blodtryk særligt når du rejser dig op) </p>
</li>
<li>
<p>sammensnøring af musklerne i luftvejene, som forårsager hvæsende vejrtrækning 
(bronkospasme), inflammation (betændelseslignende reaktion), irritation i lungerne, halsen 
eller bihulerne, åndenød, løbende næse </p>
</li>
<li>
<p>opkastning, diarré, mavesmerter, irritation eller sår i svælg eller mund, synkebesvær, 
forstoppelse, fordøjelsesproblemer </p>
</li>
<li>
<p>spiseforstyrrelser, for lille fødeindtagelse, der medfører vægttab </p>
</li>
<li>
<p>nældefeber, øget svedtendens, nattesved </p>
</li>
<li>
<p>muskelproblemer, f.eks. muskelkramper, led-eller muskelsmerter, ryg-og nakkesmerter </p>
</li>
<li>
<p>almen utilpashed og træthed, rystelser, tegn på influenza </p>
</li>
<li>
<p>svigt af mange organer. </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 patienter): </p>
<ul>
<li>
<p>blodprop, nedsat produktion og hurtigere ødelæggelse af røde blodlegemer (aplastisk 
hæmolytisk anæmi), hævede eller forstørrede lymfekirtler </p>
</li>
<li>
<p>dårligt humør og manglende interesse eller glæde ved ting, nervøsitet </p>
</li>
<li>
<p>smagsforstyrrelser, f.eks. at ting smager anderledes, end de plejer </p>
</li>
<li>
<p>hjerteproblemer, f.eks. nedsat hjerteaktion eller brystsmerter (angina) </p>
</li>
<li>
<p>astma, kroppens organer får for lidt ilt </p>
</li>
<li>
<p>opsvulmet mave. </p>
</li>
</ul>
<p>Meget sjældne bivirkninger (kan forekomme hos op til 1 ud af 10.000 patienter): </p>
<ul>
<li>
<p>kortvarig stigning i antallet af bestemte antistoffer kaldet immunglobuliner i blodet (IgM), 
kemiske forstyrrelser i blodet forårsaget af nedbrydningen af døende kræftceller </p>
</li>
<li>
<p>nerveskader i arme og ben, lammelse af ansigtet </p>
</li>
<li>
<p>hjertesvigt </p>
</li>
<li>
<p>irritation i blodkarrene, der kan medføre hudsymptomer </p>
</li>
<li>
<p>vejrtrækningsstop </p>
</li>
<li>
<p>beskadigelse af tarmvæggen 
• svære hudproblemer med blister, der kan være livsfarlige. Rødme, ofte forbundet med blærer, 
kan forekomme på hud og slimhinder, såsom på indersiden af munden, kønsdele eller øjenlåg, 
og kan være ledsaget af feber </p>
</li>
<li>
<p>nyresvigt </p>
</li>
<li>
<p>svært synstab </p>
</li>
</ul>
<p>Ikke kendt (det vides ikke, hvor ofte disse bivirkninger forekommer): </p>
<ul>
<li>
<p>forsinket fald i de hvide blodlegemer </p>
</li>
<li>
<p>nedsat antal blodplader umiddelbart efter infusionen; dette kan rette sig, men kan i sjældne 
tilfælde være dødeligt </p>
</li>
<li>
<p>høretab og tab af andre sanser </p>
</li>
<li>
<p>hjerne- og hjernehinde infektion/betændelse (enteroviral meningoencefalitis) </p>
</li>
</ul>
<p>Børn og unge med non-Hodgkin-lymfom: 
Generelt svarede bivirkninger hos børn og unge med non-Hodgkin-lymfom til dem, der ses hos voksne 
med non-Hodgkin-lymfom eller kronisk lymfatisk leukæmi. De mest almindelige bivirkninger var 
feber med lavt antal af en type hvide blodlegemer (neutrofiler), infektioner eller sår i mundens 
slimhinder og allergiske reaktioner (overfølsomhed). </p>
<p>b) 
Hvis du eller dit barn behandles for granulomatose med polyangiitis eller mikroskopisk 
polyangiitis </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 patienter): </p>
<ul>
<li>
<p>infektioner som f.eks. luftvejsinfektioner, urinvejsinfektion (smerter ved vandladning), 
forkølelse og herpesudbrud </p>
</li>
<li>
<p>allergiske reaktioner, som normalt forekommer under infusionen, men kan forekomme i op 
til 24 timer efter infusion </p>
</li>
<li>
<p>diarré </p>
</li>
<li>
<p>hoste eller kortåndethed </p>
</li>
<li>
<p>næseblod </p>
</li>
<li>
<p>forhøjet blodtryk </p>
</li>
<li>
<p>smerter i led eller ryg </p>
</li>
<li>
<p>muskelspasmer eller -rysten </p>
</li>
<li>
<p>svimmelhed </p>
</li>
<li>
<p>rysten (ofte på hænderne) </p>
</li>
<li>
<p>søvnbesvær </p>
</li>
<li>
<p>hævede hænder eller ankler </p>
</li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter): </p>
<ul>
<li>
<p>fordøjelsesbesvær </p>
</li>
<li>
<p>forstoppelse </p>
</li>
<li>
<p>udslæt, inklusive akne eller uren hud </p>
</li>
<li>
<p>ansigtsrødme eller rød hud 
•     feber </p>
</li>
<li>
<p>stoppet eller løbende næse </p>
</li>
<li>
<p>muskelkramper eller ømme muskler </p>
</li>
<li>
<p>smerter i muskler eller hænder og fødder </p>
</li>
<li>
<p>lavt antal røde blodlegemer (anæmi) </p>
</li>
<li>
<p>lavt antal blodplader </p>
</li>
<li>
<p>forhøjet kalium i blodet </p>
</li>
<li>
<p>ændringer i hjerterytmen, eller hjertet slår hurtigere end normalt </p>
</li>
</ul>
<p>Meget sjældne bivirkninger (kan forekomme hos op til 1 ud af 10.000 patienter): </p>
<ul>
<li>
<p>alvorlige, eventuelt livstruende hudsygdomme med blærer. Rødme, ofte forbundet med 
blærer, kan forekomme på hud og slimhinder, såsom på indersiden af munden, kønsdele eller 
øjenlåg og kan være ledsaget af feber </p>
</li>
<li>
<p>genopblussen af tidligere hepatitis B-infektion </p>
</li>
</ul>
<p>Ikke kendt (hyppigheden kan ikke estimeres ud fra tilgængelige data):  </p>
<ul>
<li>
<p>alvorlig virusinfektion </p>
</li>
<li>
<p>hjerne- og hjernehinde infektion/betændelse (enteroviral meningoencefalitis) </p>
</li>
</ul>
<p>Børn og unge med granulomatose med polyangiitis eller mikroskopisk polyangiitis 
Bivirkninger hos børn og unge med granulomatose med polyangiitis eller mikroskopisk polyangiitis 
var generelt af samme type som set hos voksne med granulomatose med polyangiitis eller 
mikroskopisk polyangiitis. De mest almindelige bivirkninger er infektioner, allergiske reaktioner og 
kvalme. </p>
<p>c)      Hvis du behandles for pemfigus vulgaris </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 patienter): 
• allergiske reaktioner, som normalt forekommer under infusionen, men kan forekomme i op til 
24 timer efter infusion 
• hovedpine 
• infektioner såsom infektioner i brystet 
• langvarig depression 
• hårtab </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter): 
• infektioner som f.eks. forkølelse herpesudbrud og øjeninfektion, trøske og  urinvejsinfektioner 
(smerter ved vandladning) 
• humørsvingninger såsom irritabilitet og depression 
• hudsygdomme såsom kløe, nældefeber og godartede knuder 
• træthed og svimmelhed 
• feber 
• led- eller rygsmerter<br />
• smerter i maven 
• smerter i musklerne 
• hjertet slår hurtigere end normalt </p>
<p>Ikke kendt (hyppigheden kan ikke estimeres ud fra tilgængelige data):<br />
• alvorlig virusinfektion 
• hjerne- og hjernehinde infektion/betændelse (enteroviral meningoencefalitis) </p>
<p>Blitzima kan også ændre resultaterne på de blodprøver, som lægen har bestilt. 
Hvis du får Blitzima sammen med anden medicin, kan nogle bivirkninger være forårsaget af den 
anden medicin. </p>
<p>Indberetning af bivirkninger </p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store blitzima"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store blitzima"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og hætteglasset efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2 °C – 8 °C). Opbevar hætteglasset i den ydre karton for at beskytte mod lys. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Blitzima indeholder: </p>
<ul>
<li>
<p>Aktivt stof: Rituximab.<br />
Hætteglasset med 10 mL indeholder 100 mg rituximab (10 mg/mL). 
Hætteglasset med 50 mL indeholder 500 mg rituximab (10 mg/mL). </p>
</li>
<li>
<p>Øvrige indholdsstoffer: Natriumchlorid, trinatriumcitratdihydrat, polysorbat 80 og vand til 
injektionsvæsker (se afsnit 2 “Blitzima indeholder natrium”). </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Blitzima er en klar, farveløs opløsning, leveret som koncentrat til infusionsvæske, opløsning.<br />
10 mL hætteglas - pakning med 2 hætteglas 
50 mL hætteglas - pakning med 1 hætteglas </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Celltrion Healthcare Hungary Kft. 
1062 Budapest 
Váci út 1-3. WestEnd Office Building B torony<br />
Ungarn </p>
<p>Fremstiller </p>
<p>Millmount Healthcare Ltd. 
Block 7, City North Business Campus,<br />
Stamullen, Co. Meath K32 YD60,<br />
Irland </p>
<p>Nuvisan GmbH 
Wegenerstrasse 13, Ludwigsfeld 
89231 Neu-Ulm, Bavaria 
Tyskland </p>
<p>Nuvisan France SARL<br />
2400, Route des Colles,  06410, Biot,<br />
Frankrig </p>
<p>KYMOS S.L. 
Ronda de Can Fatjó, 7B Parc Tecnològic del Vallès<br />
08290 – Cerdanyola del Vallès, Barcelona,<br />
Spanien </p>
<p>Midas Pharma GmbH<br />
Rheinstrasse 49, West Ingelheim Am Rhein,<br />
Rhineland-Palatinate 55218 Ingelheim,<br />
Tyskland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Celltrion Healthcare Belgium BVBA 
Tél/Tel: +32 1528 7BEinfo@celltrionhc.com<br />
Lietuva 
Celltrion Healthcare Hungary Kft. 
 Tel: +36 1 231 0 
България 
Celltrion Healthcare Hungary Kft. 
 Tel: +36 1 231 0 
Luxembourg/Luxemburg 
Celltrion Healthcare Belgium BVBA 
Tél/Tel: +32 1528 7BEinfo@celltrionhc.com  </p>
<p>Česká republika 
Celltrion Healthcare Hungary Kft. 
 Tel: +36 1 231 0 
Magyarország 
Celltrion Healthcare Hungary Kft. 
 Tel: +36 1 231 0 </p>
<p>Danmark 
Orion Pharma A/S<br />
Tlf: + 45 86 14 00 Malta 
Mint Health Ltd. 
Tel: +356 2093 9800  </p>
<p>Deutschland 
Celltrion Healthcare Deutschland GmbH 
Tel. +49 (0)30 346494 
infoDE@celltrionhc.com 
Nederland 
Celltrion Healthcare Netherlands B.V 
Tel: +31 20 888 7NLinfo@celltrionhc.com </p>
<p>Eesti 
Orion Pharma Eesti OÜ 
Tel: + 372 6 644<br />
Norge 
Orion Pharma AS 
Tlf: + 47 40 00 42  </p>
<p>Ελλάδα 
ΒΙΑΝΕΞ Α.Ε. 
Τηλ: +30 210 8009111 –<br />
España 
Kern Pharma, S.L. 
Tel: +34 93 700 2Österreich 
Astro-Pharma GmbH 
Tel: +43 1 97 99<br />
Polska 
Celltrion Healthcare Hungary Kft. 
 Tel: +36 1 231 0 </p>
<p>France 
CELLTRION HEALTHCARE FRANCE SAS 
Tél: +33 (0)1 71 25 27 Portugal 
PharmaKERN Portugal – Produtos Farmacêuticos, 
Sociedade Unipessoal, Lda. 
Tel: +351 214 200<br />
Hrvatska 
Oktal Pharma d.o.o. 
Tel: +385 1 6595<br />
România 
Celltrion Healthcare Hungary Kft. 
 Tel: +36 1 231 0 
Ireland 
Celltrion Healthcare Ireland Limited 
Tel: +353 1 223 4enquiry_ie@celltrionhc.com </p>
<p>Slovenija 
OPH Oktal Pharma d.o.o.<br />
Tel: +386 1 519 29  </p>
<p>Ísland 
Vistor hf.<br />
Sími: +354 535 7 
Slovenská republika 
Celltrion Healthcare Hungary Kft. 
 Tel: +36 1 231 0Italia 
Celltrion Healthcare Italy S.R.L 
Tel: +39 0247 927celltrionhealthcare_italy@legalmail.it  </p>
<p>Suomi/Finland 
Orion Pharma 
Puh/Tel: + 358 10 4 
Κύπρος 
C.A. Papaellinas Ltd 
Τηλ: +357 22741 
Sverige 
Orion Pharma AB 
Tel: + 46 8 623 64<br />
Latvija 
Celltrion Healthcare Hungary Kft. 
 Tel: +36 1 231 0United Kingdom (Northern Ireland) 
Celltrion Healthcare Ireland Limited 
Tel: +353 1 223 4enquiry_ie@celltrionhc.com </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-8efc3218e58b030bcc0685f059870454
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for blitzima Package Leaflet for language en"
Description: "ePI document Bundle for blitzima Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-8efc3218e58b030bcc0685f059870454"
* entry[0].resource = composition-en-8efc3218e58b030bcc0685f059870454

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8efc3218e58b030bcc0685f059870454"
* entry[=].resource = mp8efc3218e58b030bcc0685f059870454
                            
                    
Instance: bundlepackageleaflet-da-8efc3218e58b030bcc0685f059870454
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for blitzima Package Leaflet for language da"
Description: "ePI document Bundle for blitzima Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-8efc3218e58b030bcc0685f059870454"
* entry[0].resource = composition-da-8efc3218e58b030bcc0685f059870454

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8efc3218e58b030bcc0685f059870454"
* entry[=].resource = mp8efc3218e58b030bcc0685f059870454
                            
                    



Instance: mp8efc3218e58b030bcc0685f059870454
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product blitzima"
Description: "blitzima"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Blitzima 100 mg concentrate for solution for infusion"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Blitzima is indicated in adults for the following indications:"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "blitzima"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 8efc3218e58b030bcc0685f059870454ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "blitzima"

* status = #current
* mode = #working

* title = "List of all ePIs associated with blitzima"

* subject = Reference(mp7fc8cfe8242eb0119d3b2e1dc1d125b7)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#blitzima "blitzima"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-8efc3218e58b030bcc0685f059870454) // blitzima en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-8efc3218e58b030bcc0685f059870454) // blitzima da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-8efc3218e58b030bcc0685f059870454
InstanceOf: List

* insert 8efc3218e58b030bcc0685f059870454ListRuleset
    